Revolution Medicines, Inc. (NASDAQ: RVMD) announced that its Chief Operating Officer, Margaret Horn, sold 4,847 shares of the company’s stock on December 16, 2023. The shares were sold at an average price of $76.82, resulting in a total transaction value of $372,346.54. Following this sale, Horn retains ownership of 141,053 shares in Revolution Medicines, which are valued at approximately $10,835,691.46. This sale signifies a decrease of 3.32% in her ownership stake in the company.
Following the announcement of the stock sale, shares of Revolution Medicines saw a slight decline of 1.0%, trading at $75.96 during mid-day trading on the Thursday following the transaction. The trading volume reached 2,749,530 shares, surpassing the average volume of 2,009,908 shares. Currently, Revolution Medicines holds a market capitalization of $14.68 billion, with a price-to-earnings (P/E) ratio of -14.69 and a beta of 0.96.
Recent Financial Performance and Market Analysts’ Outlook
Revolution Medicines recently reported its quarterly earnings on November 5, 2023. The company posted an earnings per share (EPS) of ($1.61), which fell short of analysts’ expectations of ($1.39) by $0.22. In the same quarter of the previous year, the company recorded an EPS of ($0.94). Analysts forecast that Revolution Medicines will report an EPS of ($3.49) for the current fiscal year.
Several financial analysts have provided insights into Revolution Medicines’ stock performance. UBS Group upgraded the stock to a “strong-buy” rating on December 4, 2023. Needham & Company LLC raised their target price from $66.00 to $72.00 and rated the stock as a “buy” in a report issued on November 6, 2023. Similarly, The Goldman Sachs Group increased their target from $65.00 to $73.00 with a “buy” rating on September 12, 2023. Wedbush also raised their target from $77.00 to $80.00, giving an “outperform” rating on November 6, 2023. Truist Financial began coverage with a “buy” rating and a target price of $99.00 on September 5, 2023.
A total of four analysts have rated the stock as a “strong buy,” while thirteen have assigned a “buy” rating. There is one “sell” rating. According to data from MarketBeat.com, the consensus rating is “buy,” with a consensus target price of $78.50.
Company Overview and Research Focus
Revolution Medicines, Inc. is a clinical-stage precision oncology company focused on developing innovative targeted therapies for cancers that are dependent on RAS mutations. The company’s research and development pipeline includes RAS(ON) inhibitors designed for use either as monotherapy or in combination with other therapies, as well as RAS companion inhibitors aimed at enhancing treatment strategies.
With ongoing developments in its research pipeline and a robust market presence, Revolution Medicines continues to attract interest from investors and analysts alike. The company remains committed to addressing high unmet needs in the oncology sector with its groundbreaking therapeutic approaches.
